BioInvent International AB (BINV) - Net Assets

Latest as of June 2025: Skr810.74 Million SEK ≈ $87.25 Million USD

Based on the latest financial reports, BioInvent International AB (BINV) has net assets worth Skr810.74 Million SEK (≈ $87.25 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr916.67 Million ≈ $98.65 Million USD) and total liabilities (Skr105.93 Million ≈ $11.40 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BioInvent International AB (BINV) tangible net worth to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr810.74 Million
% of Total Assets 88.44%
Annual Growth Rate 7.4%
5-Year Change 19.14%
10-Year Change 2907.45%
Growth Volatility 157.68

BioInvent International AB - Net Assets Trend (2000–2024)

This chart illustrates how BioInvent International AB's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of BioInvent International AB to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for BioInvent International AB (2000–2024)

The table below shows the annual net assets of BioInvent International AB from 2000 to 2024. For live valuation and market cap data, see BioInvent International AB market capitalisation.

Year Net Assets Change
2024-12-31 Skr885.82 Million
≈ $95.33 Million		 -32.37%
2023-12-31 Skr1.31 Billion
≈ $140.95 Million		 -18.45%
2022-12-31 Skr1.61 Billion
≈ $172.84 Million		 +17.49%
2021-12-31 Skr1.37 Billion
≈ $147.11 Million		 +83.86%
2020-12-31 Skr743.50 Million
≈ $80.01 Million		 +338.81%
2019-12-31 Skr169.44 Million
≈ $18.23 Million		 +93.37%
2018-12-31 Skr87.62 Million
≈ $9.43 Million		 -32.72%
2017-12-31 Skr130.22 Million
≈ $14.01 Million		 -43.49%
2016-12-31 Skr230.44 Million
≈ $24.80 Million		 +682.36%
2015-12-31 Skr29.45 Million
≈ $3.17 Million		 -43.82%
2014-12-31 Skr52.43 Million
≈ $5.64 Million		 +6.98%
2013-12-31 Skr49.01 Million
≈ $5.27 Million		 +2.90%
2012-12-31 Skr47.62 Million
≈ $5.13 Million		 -65.48%
2011-12-31 Skr137.95 Million
≈ $14.85 Million		 +85.94%
2010-12-31 Skr74.19 Million
≈ $7.98 Million		 +33.36%
2009-12-31 Skr55.63 Million
≈ $5.99 Million		 -75.95%
2008-12-31 Skr231.30 Million
≈ $24.89 Million		 +8.02%
2007-12-31 Skr214.12 Million
≈ $23.04 Million		 +94.38%
2006-12-31 Skr110.15 Million
≈ $11.85 Million		 -49.70%
2005-12-31 Skr219.00 Million
≈ $23.57 Million		 +2.97%
2004-12-31 Skr212.68 Million
≈ $22.89 Million		 -30.26%
2003-12-31 Skr304.96 Million
≈ $32.82 Million		 -22.65%
2002-12-31 Skr394.25 Million
≈ $42.43 Million		 +1.50%
2001-12-31 Skr388.42 Million
≈ $41.80 Million		 +143.32%
2000-12-31 Skr159.63 Million
≈ $17.18 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to BioInvent International AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 51812.7% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock Skr13.16 Million 1.49%
Other Comprehensive Income Skr1.00K 0.00%
Other Components Skr3.76 Billion 424.38%
Total Equity Skr885.82 Million 100.00%

BioInvent International AB Competitors by Market Cap

The table below lists competitors of BioInvent International AB ranked by their market capitalization.

Company Market Cap
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
NASDAQ:OACC
 $210.69 Million
HUYA Inc
F:HY5A
 $210.73 Million
Solara Active Pharma Sciences Limited
NSE:SOLARA
 $210.79 Million
Sierra Madre Gold and Silver Ltd
V:SM
 $210.82 Million
Alfen Beheer BV
AS:ALFEN
 $210.60 Million
Circio Holding ASA
OL:CRNA
 $210.51 Million
Sheng Yu Steel Co Ltd
TW:2029
 $210.47 Million
Yantai Changyu Pioneer Wine
SHE:200869
 $210.43 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BioInvent International AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,309,727,000 to 885,815,000, a change of -423,912,000 (-32.4%).
  • Net loss of 429,375,000 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Skr-429.38 Million -48.47%
Other Changes Skr5.46 Million +0.62%
Total Change Skr- -32.37%

Book Value vs Market Value Analysis

This analysis compares BioInvent International AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.21x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 0.12x to 2.21x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 Skr243.54 Skr29.75 x
2003-12-31 Skr184.95 Skr29.75 x
2004-12-31 Skr128.98 Skr29.75 x
2005-12-31 Skr132.37 Skr29.75 x
2006-12-31 Skr44.74 Skr29.75 x
2007-12-31 Skr80.15 Skr29.75 x
2008-12-31 Skr79.60 Skr29.75 x
2009-12-31 Skr19.15 Skr29.75 x
2010-12-31 Skr23.46 Skr29.75 x
2011-12-31 Skr41.16 Skr29.75 x
2012-12-31 Skr12.76 Skr29.75 x
2013-12-31 Skr12.86 Skr29.75 x
2014-12-31 Skr11.66 Skr29.75 x
2015-12-31 Skr5.06 Skr29.75 x
2016-12-31 Skr22.76 Skr29.75 x
2017-12-31 Skr10.47 Skr29.75 x
2018-12-31 Skr6.34 Skr29.75 x
2019-12-31 Skr9.18 Skr29.75 x
2020-12-31 Skr25.89 Skr29.75 x
2021-12-31 Skr25.24 Skr29.75 x
2022-12-31 Skr26.11 Skr29.75 x
2023-12-31 Skr19.91 Skr29.75 x
2024-12-31 Skr13.46 Skr29.75 x

Capital Efficiency Dashboard

This dashboard shows how efficiently BioInvent International AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -48.47%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -960.87%
  • • Asset Turnover: 0.05x
  • • Equity Multiplier: 1.12x
  • Recent ROE (-48.47%) is above the historical average (-86.10%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 11.71% 53.03% 0.20x 1.13x Skr6.74 Million
2003 29.40% 134.39% 0.19x 1.13x Skr59.16 Million
2004 -43.50% -157.48% 0.25x 1.12x Skr-113.78 Million
2005 -63.86% -496.00% 0.11x 1.22x Skr-161.76 Million
2006 -98.80% -214.12% 0.34x 1.35x Skr-119.85 Million
2007 -7.52% -11.22% 0.53x 1.27x Skr-37.50 Million
2008 7.03% 6.45% 0.85x 1.28x Skr-6.88 Million
2009 -317.55% -219.02% 0.64x 2.27x Skr-182.22 Million
2010 -173.07% -154.95% 0.60x 1.86x Skr-135.82 Million
2011 -48.61% -53.79% 0.61x 1.49x Skr-80.85 Million
2012 -394.43% -437.40% 0.37x 2.45x Skr-192.61 Million
2013 -36.81% -22.08% 1.00x 1.66x Skr-22.94 Million
2014 -102.97% -115.03% 0.63x 1.41x Skr-59.23 Million
2015 -307.87% -569.43% 0.29x 1.85x Skr-93.63 Million
2016 -27.16% -87.80% 0.26x 1.20x Skr-85.63 Million
2017 -77.20% -223.33% 0.26x 1.31x Skr-113.55 Million
2018 -140.56% -319.51% 0.32x 1.37x Skr-131.93 Million
2019 -82.10% -148.41% 0.41x 1.33x Skr-156.06 Million
2020 -10.31% -52.02% 0.18x 1.08x Skr-151.02 Million
2021 -20.41% -1439.13% 0.01x 1.06x Skr-415.66 Million
2022 -2.12% -10.45% 0.19x 1.07x Skr-194.70 Million
2023 -25.22% -462.22% 0.05x 1.07x Skr-461.28 Million
2024 -48.47% -960.87% 0.05x 1.12x Skr-517.96 Million

Industry Comparison

This section compares BioInvent International AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $194,710,667
  • Average return on equity (ROE) among peers: -45.55%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
BioInvent International AB (BINV) Skr810.74 Million 11.71% 0.13x $210.68 Million
2cureX AB (2CUREX) $43.03 Million -69.18% 0.11x $4.92 Million
Ascelia Pharma AB (publ) (ACE) $236.06 Million -41.81% 0.08x $39.32 Million
AcouSort AB (ACOU) $9.96 Million -8.34% 0.21x $11.07 Million
Active Biotech AB (ACTI) $46.67 Million -106.88% 0.22x $103.60 Million
Alzinova AB (ALZ) $123.82 Million -16.60% 0.08x $7.34 Million
AlzeCure Pharma (ALZCUR) $60.48 Million -92.65% 0.17x $16.57 Million
Annexin Pharmaceuticals AB (ANNX) $46.73 Million -111.59% 0.13x $11.40 Million
Alligator Bioscience AB (ATORX) $396.97 Million 52.24% 0.05x $12.86 Million
BioArctic AB (publ) (BIOA-B) $788.68 Million -15.19% 0.14x $2.51 Billion

About BioInvent International AB

ST:BINV Sweden Biotechnology
Market Cap
$210.68 Million
Skr1.96 Billion SEK
Market Cap Rank
#16440 Global
#270 in Sweden
Share Price
Skr29.75
Change (1 day)
+1.02%
52-Week Range
Skr21.25 - Skr41.05
All Time High
Skr95.26
Categories
Companies in Sweden Biotechnology
About

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more